Autoimmune RORγt Program May Portend Change Of Direction For Vitae

The drug-discovery specialist is mulling several potential partners for its ROR gamma t inhibitor program, which has potential in autoimmune indications. Two cash-generating deals with Boehringer Ingelheim have made the clinical-stage company self-sufficient for nearly a decade.

Vitae Pharmaceuticals Inc. tells a different story than many other clinical-stage companies, but then how many biotechs without a commercial product have not needed to raise funds in nearly nine years? Focused on structure-based drug design, the Ft. Washington, Pa., firm is nearing an inflection point as it decides which among several suitors to partner with on a ROR gamma t inhibitor program that could offer utility in multiple autoimmune indications.

Using a discovery platform derived from computational chemistry research initiated at Harvard University, Vitae has generated roughly $130 million...

More from United States

More from North America